NasdaqCM - Delayed Quote USD

Avenue Therapeutics, Inc. (ATXI)

1.8114

-0.0786

(-4.16%)

At close: January 10 at 4:00:00 PM EST

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. “We have gen

GlobeNewswire last month

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be av

GlobeNewswire 3 months ago

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics to Participate in Upcoming Investor Conferences

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Loc

GlobeNewswire 4 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-te

GlobeNewswire 4 months ago

FBIO
-2.40%
FBIOP

DERM
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction - MIAMI, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, toda

GlobeNewswire 5 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The presentation will be available to registered attendees for on-dema

GlobeNewswire 6 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“

GlobeNewswire 7 months ago

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024. “The first quarter was incredibly p

GlobeNewswire 7 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The exercised warrants are comprised of warrants to purchase sh

GlobeNewswire 8 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics Announces Reverse Stock Split

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on Apr

GlobeNewswire 8 months ago

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi

GlobeNewswire 9 months ago

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeutics (ASENT) Annual Meetings and in publication Drug Development Research - - Final agreement reached with FDA on study design and analysis approach for Phase 3 safety study of IV tramadol – MIAMI, March 18, 2024 (G

GlobeNewswire 9 months ago

ATXI
-4.16%
FBIO
-2.40%
FBIOP
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.

GlobeNewswire 9 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappe

GlobeNewswire 9 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy-MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in

GlobeNewswire 10 months ago

FBIO
-2.40%
FBIOP

ATXI
-4.16%
Sidoti Events, LLC's Virtual January Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January ...

ACCESSWIRE 11 months ago

CVEO

LLKKF

BTM

Performance Overview

Return	ATXI	S&P 500
YTD	-6.63%	-1.35%
1-Year	-87.22%	+22.51%
3-Year	-99.82%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Avenue Therapeutics Announces Reverse Stock Split

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Performance Overview